The effect of lixisenatide on post-prandial blood glucose and glucagon in type 1 diabetes
C. Ballav\textsuperscript{1}, A. Dhere\textsuperscript{1}, O. Agbaje\textsuperscript{2}, I. Kennedy\textsuperscript{2}, R.R. Holman\textsuperscript{2,3}, K.R. Owen\textsuperscript{1,3};
\textsuperscript{1}Oxford Centre for Diabetes Endocrinology and Metabolism, Oxford, \textsuperscript{2}Diabetes Trial Unit, Oxford, \textsuperscript{3}Oxford Biomedical Research Centre, Oxford, UK.

Background and aims: The glucagon-like peptide-1 receptor agonist, Lixisenatide (Lix), suppresses glucagon and reduces hyperglycaemia in type 2 diabetes. We studied the effect of Lix on post-prandial blood glucose (PPBG) and glucagon in type 1 diabetes (T1D).

Materials and methods: In a double-blinded, placebo-controlled, crossover study, 25 patients with T1D (13 females, mean±SE HbA\textsubscript{1c} 65.6±8.1 mmol/mol, BMI 27.0±3.6 Kg/m\textsuperscript{2}) received treatment in random order with Lix and placebo (Plac) in addition to their usual insulin therapy for four weeks, with a four week washout period in between. Participants had continuous glucose monitoring (CGM) for at least 3 days before and at the end of each treatment period, as well as post treatment standard mixed meal tests (MMT; Fortisip 360 Kcal) and hyperinsulinaemic hypoglycaemic clamps (target glucose 2.5 mmol/L). (See Figure). The primary outcome was defined as the proportion of CGM readings in the range 4 to 10 mmol/L during the 3-hour post-prandial period.

Results: The mean±SE percentage of PPBG CGM readings in range was similar before and after treatment and for each meal for Lix compared with Plac (breakfast 45.4±6.0 vs. 44.3±6.0, p=0.9, lunch 45.5±5.8 vs. 50.6±5.3, p=0.6, and dinner 43.0±6.7 vs. 47.7±5.6, p=0.6). Mean HbA1c did not change during treatment periods and was similar between Lix and Plac (64.7±1.6 vs. 64.1±1.6 mmol/mol, p=0.3). The overall daily prandial insulin dose post-treatment was significantly less after Lix compared with Plac (-0.7±0.6 vs. +2.4±0.7 units/day, p=0.004), but the total insulin dose was not different between treatments. The post MMT mean±SE 120 minute glucose area under the curve (AUC) was lower with Lix compared with Plac (392.0±167.7 vs. 628.1±132.5 mmol/L x min, p< 0.001), as was the corresponding glucagon AUC (140.0±110.0 vs. 304.2±148.2 nmol/L x min, p<0.001). Glucagon values at a blood glucose level of 2.4 mmol/L during the hypoglycaemic clamp, were similar for Lix compared with Plac (3.1±3.7 vs. 2.6±1.7 nmol/L, p=0.7). Mean adrenaline, noradrenaline, cortisol and pancreatic polypeptide values did not differ during the clamp between Lix and Plac.

Conclusion: Lixisenatide suppresses glucagon and may reduce post prandial glycaemia without compromising counter-regulatory responses during hypoglycaemia in T1D.

Clinical Trial Registration Number: ISRCTN no. 00290196
Supported by: Funding for this Investigator Sponsored research was provided by Sanofi
Disclosure: C. Ballav: None.